Information Provided By: 
Fly News Breaks for April 24, 2018
EPZM
Apr 24, 2018 | 07:58 EDT
Leerink analyst Geoffrey Porges notes that Epizyme announced a partial clinical hold for its lead drug tazemetostat due to the occurrence of a single case of T cell lymphoma in a patient with a long treatment history with the drug for a rare solid tumor. The analyst does not see this case as a major setback, and expects the clinical program to resume enrollment in a matter of weeks once the study documents are updated. Porges reiterates an Outperform rating and $24 price target on the shares.
News For EPZM From the Last 2 Days
There are no results for your query EPZM
